Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioGend Therapeutics CoROCO:6733 -2.50%73 Current Ratio is 17.60 as of Dec. 2025, which is 10% below its 10-year median of 19.60. GuruFocus rates ROCO:6733 with a GF Score™ of 73/100 and a GF Value™ of NT$70.22 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 1,411 Biotechnology companies, BioGend Therapeutics Co ranks better than 89.72% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. BioGend Therapeutics Co's current ratio for the quarter that ended in Dec. 2025 was 17.60.
BioGend Therapeutics Co has a current ratio of 17.60. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for BioGend Therapeutics Co's Current Ratio or its related term are showing as below:
ROCO:6733'
s Current Ratio Range Over the Past 10 Years
Min: 2.91 Med: 19.6 Max: 31.59
Current: 17.6
During the past 10 years, BioGend Therapeutics Co's highest Current Ratio was 31.59. The lowest was 2.91. And the median was 19.60.
ROCO:6733's Current Ratio is ranked better than 89.72% of 1411
companies
in the Biotechnology industry
Industry Median: 3.88
vs ROCO:6733: 17.60
BioGend Therapeutics Co (ROCO:6733) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
BioGend Therapeutics Co Current Ratio Related Terms
BioGend Therapeutics Co Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6733 vs VRTX, REGN, ALNY: Current Ratio Comparison
For the Biotechnology subindustry, BioGend Therapeutics Co's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioGend Therapeutics Co Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioGend Therapeutics Co's Current Ratio distribution charts can be found below:
* The bar in red indicates where BioGend Therapeutics Co's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioGend Therapeutics Co (ROCO:6733) has a Current Ratio of 17.60 as of Dec. 2025. This is 10% below median its historical median of 19.60. Over the past decade, BioGend Therapeutics Co's Current Ratio has ranged from 2.91 to 31.59. According to the industry distribution chart, BioGend Therapeutics Co ranks #145 out of 1411 companies in the Biotechnology industry, placing it in the top 10.3%.
Is BioGend Therapeutics Co's Current Ratio too high?
BioGend Therapeutics Co's current Current Ratio of 17.60 is 10% below median its 10-year median of 19.60. Over the past 10 years, this metric has ranged from a low of 2.91 to a high of 31.59. The Biotechnology industry median Current Ratio is 3.88. BioGend Therapeutics Co's value of 17.60 is 353.6% above this industry median. Based on the distribution chart, BioGend Therapeutics Co ranks #145 out of 1411 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, BioGend Therapeutics Co has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioGend Therapeutics Co's Current Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BioGend Therapeutics Co ranks #145 out of 1411 companies for Current Ratio. This places BioGend Therapeutics Co in the top 10% of its industry — outperforming the majority of peers. The industry median Current Ratio is 3.88. BioGend Therapeutics Co's value of 17.60 is 353.6% above this benchmark. Historically, BioGend Therapeutics Co's own Current Ratio has ranged from 2.91 to 31.59 over the past decade. While the company's 10-year median is 19.60 vs. the industry median of 3.88, BioGend Therapeutics Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.88, based on 1,411 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioGend Therapeutics Co's current Current Ratio of 17.60 is 353.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioGend Therapeutics Co's current Current Ratio is 17.60, which is 10% below median its own 10-year median of 19.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioGend Therapeutics Co stock overvalued right now?
Based on GuruFocus' analysis, BioGend Therapeutics Co (ROCO:6733) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$70.22, compared to a current price of NT$25.35 — trading 63.9% below its estimated fair value. The current Current Ratio is 17.60, which is 10% below median its 10-year median of 19.60 and 353.6% above the Biotechnology industry median of 3.88. BioGend Therapeutics Co's overall GF Score™ is 73/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For BioGend Therapeutics Co (ROCO:6733), the current Current Ratio is 17.60 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioGend Therapeutics Co (ROCO:6733) Overvalued in 2026?
Based on GuruFocus' analysis, BioGend Therapeutics Co stock appears to be undervalued.
The current stock price of NT$25.35 is trading 63.9% below its estimated GF Value™ of NT$70.22.
GuruFocus considers BioGend Therapeutics Co to be Significantly Undervalued.
Key valuation signals for ROCO:6733:
Current Ratio: 17.60 (10% below median its 10-year median of 19.60)
GF Value™: NT$70.22 vs. price of NT$25.35 (63.9% below fair value)
Industry Position: 353.6% above the Biotechnology median (#145 of 1411)
No single metric tells the full story. See the ROCO:6733 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioGend Therapeutics Co Ltd is a Taiwan-based company involved in the research and development of orthopedic medical equipment and related products, and the sale of related products. It is involved in the research and development of inventive cartilage repair technology and products, adipose stem cell extraction technology, and others. Geographically, the company generates a majority of its revenue from Taiwan, followed by China, Malaysia, and other regions.
73GF Score
Get the complete analysis for ROCO:6733
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6733 has been successfully added to your 
